Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Consensus PT from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have earned an average rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $4.94.

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Evercore ISI reissued an “in-line” rating and set a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Carisma Therapeutics in a research note on Monday, January 13th. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th.

Carisma Therapeutics Stock Down 4.8 %

CARM opened at $0.39 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The business’s fifty day simple moving average is $0.45 and its 200 day simple moving average is $0.69. Carisma Therapeutics has a 52 week low of $0.38 and a 52 week high of $2.60. The stock has a market cap of $16.44 million, a PE ratio of -0.25 and a beta of 1.55.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CARM. Wexford Capital LP boosted its position in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares during the period. Renaissance Technologies LLC raised its stake in shares of Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after acquiring an additional 24,600 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the period. 44.27% of the stock is owned by hedge funds and other institutional investors.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.